consider ahead result
review sever key consider ahead result
includ financi outlook revenu estim
slightli consensu recent otezla acquisit enbrel patent
file strategi earli nsclc data repatha price aimovig
launch trajectori biosimilar capit alloc recent met
manag expect continu industri consolid reinforc optim
around upcom catalyst bullish stanc base long-term stabl
revenu forecast oper margin expans updat model
script adjust maintain outperform pt detail insid
forecast revenu adj ep slightli consensu
exhibit long-term revenu outlook gener line consensu
increas steadili oper margin
expand exhibit expect remain financi
disciplin focus capit alloc cost manag
otezla acquisit expect close add revenu
peak expect grow sale
next five year driven volum label expans strateg rational
potenti oper leverag behind otezla deal exemplifi disciplin
enbrel patent legal victori support estim
earli data encourag may support rapid file strategi
data updat expect single-arm open-label nsclc
enrol data expect next year combin plan progress
trial antibodi underway nsclc initi
mek inhibitor combo studi also initi
repatha price updat start reflect expect
strong volum growth evidenc script data view biosimilar
under-appreci option three already-approv anoth
bsufa date eu two launch biosimilar annual
two biosimilar recent launch us target annual
met manag excit potenti breakthrough
oncolog key therapeut area view differenti pipelin
driver margin expans unlock sharehold valu recent spend
reflect strateg approach increas vs sg valu pipelin
asset base sotp analysi dcf valuat support
pt exhibit
biotechnolog
discov
develop manufactur market
cancer autoimmun
diseas specialti market
year price histori
analyst certif import disclosur see disclosur
estim amgen top line remain rel stabl
margin improv sg decreas
percentag sale expect volum increas growth
product continu increas market penetr pipelin
estim revenu remain rel flat
next year margin continu expand
manag track record financi disciplin
top line believ posit maintain long-term
revenu stabil matur product declin new product
continu grow pipelin deliv steadi flow new
product addit offer dividend yield
believ provid valuat support
updat data kra inhibitor major
updat data bcma bite
data bcma hle bite
data bite
data inh iv
data inh oral
estim sell price two experiment product
low price increas exist product would
meaning upsid earn estim
experiment compound launch sooner
estim would result addit upsid estim
repatha growth slow pipelin asset fail launch
estim gradual declin revenu ep scenario
estim stock could valu rang
next month
price target base dcf valuat assum wacc residu growth rate
due declin in-lin product off-set new product pipelin long term see top line essenti stabl
forecast peak sale tezepelumab base probabl success base probabl
success omecamtiv base probabl success
believ greatest risk stock next five year disrupt continu success repatha fda
approv experiment therapi romosozumab continu success launch aimovig migrain biosimilar abp abp
abp key risk project would occur repatha growth slow experiment therapi biosimilar fail
launch
exhibit oppenheim vs consensu estim
exhibit revenu forecast increas steadili
incom estimate oppenheim vs consensu actual oppenheim estimate vs consensu updat midpoint total non-gaap cog margin rate incom ep estimate oppenheim vs consensu actual oppenheim estimate vs consensu revenu estim pipelinetot hpt secondari ckdprimari caredenosumaboncologyauto-immunegrowth factorsoth inc
exhibit valu pipelin asset tezepelumab omecamtiv
base hypothet sotp analysi
exhibit dcf valuat support pt
drug/indicationexpect launchpeak sale estim mm npv mm estimate probabl successprob-adjust npv mm sotp p-adj valu sharegrowth secondari equiti share outstand use valuat oppenheim co discount analysi except per-shar data revenu chang work work capit valu growth valu oppenheim estim compani reportsequ valu per sharetermin valu growth rate outperform
